Hedge Funds Cash in on Rare IPO

The IPO market has been slow, but biotech firm Evommune is a bright spot, with its share price up more than 21 percent since going public on November 5.

Stephen Taub November 25, 2025

The IPO market slowed down in November, thanks in part to the government shutdown.Just 11 companies have priced their offerings this month through Monday, ahead of a normally slow Thanksgiving week. This compares with 22 companies that went public in October, according to Renaissance Capital.But

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Contact Info

New York
1270 Avenue of the Americas, Suite 1100
New York, NY 10020
P: +1 212 224 3300

London
4 Bouverie Street
London EC4Y 8AX
P: +44 207 779 8888

Hong Kong
Unit 2488, 24/F
Lee Garden One,
33 Hysan Avenue
Causeway Bay, Hong Kong
P: +852 2912 8001

Corporate

About Us

Leadership Team

Careers

II Press Room

Digital

Masthead

Thought Leadership

Display Advertising

Reprints

FAQs

Events

Events Calendar

Memberships

Subscription

Subscribe to Premium

Register

Register for Free Account

Newsletters

Sign up for II newsletters

© 2025 Institutional Investor LLC. All material subject to strictly enforced copyright laws. Please read our Terms & Conditions, Modern Slavery Act Transparency Statement, Accessibility Statement and Privacy Policy before using the site.

4.12.03 build:2025-12-12 Login